Bavarian Nordic A/S (VIE:BAVA)

Market Cap	1.90B +4.8%
Revenue (ttm)	836.04M +9.2%
Net Income	184.16M +39.2%
EPS	2.36 +39.7%
Shares Out	n/a
PE Ratio	10.32
Forward PE	24.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	13
Open	24.26
Previous Close	24.34
Day's Range	23.93 - 24.50
52-Week Range	17.92 - 32.52
Beta	n/a
RSI	39.33
Earnings Date	Mar 12, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,738
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: BAVA

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.

Financial numbers in DKK